研究者詳細 - 安慶名　信也

論文 - 安慶名　信也

分割表示90 件中 1 - 20 件目／全件表示 >>

p16 Overexpression in Sinonasal Squamous Cell Carcinoma: Association with Human Papillomavirus and Prediction of Survival Outcomes

Hirakawa H, Ikegami T, Touyama M, Ooshiro Y, Higa T, Higa T, Agena S, Kinjyo H, Kondo S, Kise N, Tanaka K, Maeda H, Tamaki T, Wada N, Suzuki M

Journal of Clinical Medicine 12 ( 21 ) 6861 2023年10月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

この論文にアクセスする

DOI

Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer.

Tanaka K, Hirakawa H, Suzuki M, Higa T, Agena S, Hasegawa N, Kawakami J, Toyama M, Higa T, Kinjyo H, Kise N, Kondo S, Maeda H, Ikegami T

Current oncology (Toronto, Ont.) ( Current Oncology ) 30 ( 6 ) 5409 - 5424 2023年06月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

この論文にアクセスする

DOI
関連情報を調べる

PubMed

Human Papillomavirus Infection and EGFR Exon 20 Insertions in Sinonasal Inverted Papilloma and Squamous Cell Carcinoma.

Hirakawa H, Ikegami T, Kise N, Kinjyo H, Kondo S, Agena S, Hasegawa N, Kawakami J, Maeda H, Suzuki M

Journal of personalized medicine ( Journal of Personalized Medicine ) 13 ( 4 ) 657 2023年04月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

この論文にアクセスする

DOI
関連情報を調べる

PubMed

咽喉頭癌に対するサルベージ，コンバージョン手術

平川仁, 安慶名信也, 真栄田裕行, 鈴木幹男

日本気管食道科学会会報 ( 特定非営利活動法人日本気管食道科学会 ) 74 ( 2 ) 132 - 132 2023年04月

掲載種別: 研究論文（学術雑誌）

この論文にアクセスする

DOI
関連情報を調べる

CiNii Research

発症から2ヵ月経過し摘出に難渋した傍咽頭間隙金属異物例

武田翔吾, 真栄田裕行, 喜瀬乗基, 安慶名信也, 田中克典, 鈴木幹男

耳鼻咽喉科臨床 ( 耳鼻咽喉科臨床学会 ) 116 ( 5 ) 449 - 453 2023年 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

We encountered a case with a very small metallic foreign body inside the parapharyngeal space which was removed via the transoral approach.The patient was 36-year-old man living on a remote island. He visited the island’s clinic with a sore throat that he developed after eating fish soup. But his symptoms disappeared soon thereafter. However, the throat pain recurred after two months, and CT revealed a small foreign body inside the parapharyngeal space; the patient was immediately referred to our institution for removal of the foreign body. Since there was no abscess observed on the overlying skin and the location of the foreign body inside the parapharyngeal space could be well identified on the CT images, we attempted to remove it via a transoral approach without incising the skin. Intraoperative radiography and ultrasound were very useful to identify and remove the foreign body. However, the navigation system that we frequently use for operations of the nasal-paranasal sinuses was not as useful as we thought in this case.The transoral approach is less invasive for the patient. If there is no inflammation or abscess in the affected area and the target foreign body can be identified before or during the operation, this approach may be of some advantage over the external incision method.

この論文にアクセスする

DOI
関連情報を調べる

CiNii Research

頭頸部癌患者に対するニボルマブの使用経験

田中克典, 真栄田裕行, 金城秀俊, 安慶名信也, 平川仁, 鈴木幹男

耳鼻咽喉科臨床 ( 耳鼻咽喉科臨床学会 ) 115 ( 10 ) 875 - 881 2022年10月

掲載種別: 研究論文（その他学術会議資料等）

Therapeutic efficacy of selective intra-arterial chemoradiotherapy with docetaxel and nedaplatin for fixed bulky nodal disease in head and neck cancer of unknown primary.

Heianna J, Makino W, Hirakawa H, Agena S, Tomita H, Ariga T, Ishikawa K, Takehara S, Maemoto H, Murayama S

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery ( European Archives of Oto-Rhino-Laryngology ) 279 ( 6 ) 3105 - 3113 2022年06月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

PURPOSE: Fixed bulky nodal disease in patients with head and neck cancer of unknown primary (HNCUP) remains difficult to treat. This retrospective study evaluated the therapeutic efficacy of selective intra-arterial chemoradiotherapy with docetaxel and nedaplatin for fixed bulky nodal disease in HNCUP. METHODS: Data from seven consecutive patients with fixed bulky nodal disease in HNCUP who had undergone selective intra-arterial chemoradiotherapy were analyzed. Whole pharyngeal mucosa and all bilateral nodal areas were irradiated (total dose 50 Gy), and bulky nodal lesions were provided an additional 20 Gy. Intra-arterial chemotherapy used a combination of nedaplatin (80 mg/m2) and docetaxel (60 mg/m2). Outcome measures were local control, disease-free survival, overall survival, and adverse events. Statistical analyses were performed using the Kaplan-Meier method. RESULTS: Median follow-up period was 24 months (range 9-64). All patients had extracapsular extension (N3b) on imaging and clinical findings. Symptoms due to bulky disease were neck discomfort (100%), tumor bleeding (43%), tracheal obstruction (14%), and carotid sinus syndrome (28%). Median value for maximum diameter of cervical disease was 84 mm (range 70-107), and 3-year local control, disease-free survival, and overall survival rates were 100, 54, and 64%, respectively. Symptoms due to bulky disease disappeared in all patients after intra-arterial chemoradiotherapy. Grade 4 leukopenia occurred in two patients (28%) as an acute adverse event. No other serious acute adverse events were observed. CONCLUSION: Selective intra-arterial chemoradiotherapy with docetaxel and nedaplatin can potentially achieve both favorable local control and survival in in HNCUP with fixed bulky nodal disease.

この論文にアクセスする

DOI
関連情報を調べる

PubMed

Therapeutic efficacy of selective intraarterial chemoradiotherapy with docetaxel and nedaplatin for human papilloma virus-negative oropharyngeal cancer.

Heianna J, Makino W, Hirakawa H, Agena S, Tomita H, Ariga T, Ishikawa K, Takehara S, Kusada T, Maemoto H, Maeda H, Murayama S

Auris, nasus, larynx ( Auris Nasus Larynx ) 49 ( 3 ) 468 - 476 2022年06月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

OBJECTIVE: Human papilloma virus-negative oropharyngeal cancer has not achieved satisfactory outcomes compared with those of human papilloma virus-positive oropharyngeal cancer. This study evaluated the therapeutic efficacy of selective intraarterial chemoradiotherapy with the docetaxel and nedaplatin regimen for human papilloma virus-negative oropharyngeal cancer. METHODS: Twenty-two consecutive patients with human papilloma virus-negative oropharyngeal cancer who had undergone selective intraarterial chemoradiotherapy were retrospectively analyzed. The primary tumor and whole neck were irradiated (50 Gy). Subsequently, the primary site and metastatic lymph nodes were boosted by 20 Gy. The intraarterial chemotherapy regimen comprised a combination of nedaplatin (80 mg/m2) and docetaxel (60 mg/m2), which was initially administered at the start of radiotherapy and was given every 4 weeks for three sessions. Each intraarterial dose of an anticancer agent was determined according to the percentage of the tumor volume supplied by the target artery to the total tumor volume, which was intraoperatively measured via cone-beam computed tomography. The outcome measures were locoregional control, disease-free survival, and overall survival rates and adverse events. Statistical analyses were performed using the Kaplan-Meier method. RESULTS: The median follow-up period was 59 (range, 15-103) months. The T stage was T1/T2 in 5 patients (23%), T3 in 5 patients (23%), and T4 in 12 patients (54%). Cervical lymph node metastasis was staged as ≥N2c in 7 (32%) patients. Complete response was achieved in all patients at the first imaging examination after intraarterial chemoradiotherapy. The 5-year locoregional control, disease-free survival, and overall survival rates were 96% (95% confidence interval, 0.72-0.99), 91% (95% confidence interval, 0.68-0.98), and 100% (95% confidence interval, not available), respectively. Regarding serious acute adverse events, grade 4 laryngeal edema and leukopenia were observed in 1 (5%) and 11 patients (50%), respectively. No other serious acute adverse events were observed. CONCLUSION: Selective intraarterial chemoradiotherapy with docetaxel and nedaplatin has the potential to achieve favorable locoregional control, disease-free survival, and overall survival rates in human papilloma virus-negative oropharyngeal cancer.

この論文にアクセスする

DOI
関連情報を調べる

PubMed

当科における下咽頭癌化学放射線治療後再発例に対する救済手術の治療成績

真栄田裕行, 嘉陽祐紀, 金城秀俊, 上里迅, 安慶名信也, 田中克典, 平川仁, 鈴木幹男

頭頸部癌 ( (一社)日本頭頸部癌学会 ) 48 ( 2 ) 180 - 180 2022年05月

掲載種別: 研究論文（その他学術会議資料等）

当科における頭頸部腺様嚢胞癌の検討

安慶名信也, 金城秀俊, 上里迅, 田中克典, 平川仁, 真栄田裕行, 鈴木幹男

頭頸部癌 ( (一社)日本頭頸部癌学会 ) 48 ( 2 ) 238 - 238 2022年05月

掲載種別: 研究論文（その他学術会議資料等）

当科を受診したAYA世代頭頸部悪性腫瘍についての検討

金城秀俊, 上里迅, 安慶名信也, 田中克典, 平川仁, 真栄田裕行, 鈴木幹男

頭頸部癌 ( (一社)日本頭頸部癌学会 ) 48 ( 2 ) 235 - 235 2022年05月

掲載種別: 研究論文（その他学術会議資料等）

当科におけるNivolumabの使用経験バイオマーカーの検討

田中克典, 真栄田裕行, 平川仁, 安慶名信也, 上里迅, 金城秀俊, 嘉陽祐紀, 鈴木幹男

日本耳鼻咽喉科頭頸部外科学会会報 ( (一社)日本耳鼻咽喉科頭頸部外科学会 ) 125 ( 4 ) 718 - 718 2022年04月

掲載種別: 研究論文（その他学術会議資料等）

【耳鼻咽喉科手術における術中出血を減らす工夫】副咽頭間隙腫瘍手術

真栄田裕行, 嘉陽祐紀, 金城秀俊, 上里迅, 安慶名信也, 田中克典, 平川仁, 鈴木幹男

耳鼻咽喉科 ( (有)科学評論社 ) 1 ( 4 ) 493 - 501 2022年04月 [ 査読有り ]

掲載種別: 研究論文（その他学術会議資料等）

原著悪性疾患が疑われたアトピー性皮膚炎由来皮膚病性リンパ節症の1例

嘉陽祐紀, 真栄田裕行, 金城秀俊, 上里迅, 安慶名信也, 又吉宣, 鈴木幹男

耳鼻咽喉科・頭頸部外科 ( 株式会社医学書院 ) 94 ( 1 ) 93 - 97 2022年01月

掲載種別: 研究論文（学術雑誌）

この論文にアクセスする

DOI
関連情報を調べる

CiNii Research

頭頸部癌患者に対するニボルマブの使用経験

田中克典, 真栄田裕行, 金城秀俊, 安慶名信也, 平川仁, 鈴木幹男

耳鼻咽喉科臨床 ( 耳鼻咽喉科臨床学会 ) 115 ( 10 ) 875 - 881 2022年 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

IntroductionThe overall survival rate (OS) of head and neck carcinoma patients with resistance or intolerance to platinum agents had improved significantly with the introduction of immune checkpoint inhibitors (anti PD-1 antibody). At the same time, the proportion of patients developing immune-related adverse events (irAEs) and requiring sequential treatment is not negligible.Subject and methodsThe present study population included 42 patients, all of whom were treated with nivolumab at our institution from April 2017 to December 2019. We conducted a retrospective review of the patient data, to determine the OS, progression-free survival rate (PFS), overall response rate (ORR), and disease control rate (DCR) in the patients using the Kaplan-Meier method. Furthermore, we also determined the incidence/severity of irAE in accordance with the Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0.ResultsThe median of OS was 336 days, the 1-year OS was 49.9%, and the 2-year survival rate was 24.4%. The median PFS was 111 days, and the 1-year PFS was 17.1%. However, subgroup analysis of the patients classified by the histopathological category into the SCC group and non-SCC group revealed that while the median OS period and 1-year OS were 17.9 months and 53.2%, respectively, in the 30 cases of SCC, and 10.4 months and 41.7%, respectively, in the 12 cases of non-SCC group. There was 1 case of complete response, 5 cases of partial response, 13 cases of stable disease, and 21 cases of progressive disease. On the other hand, the ORR was 15%, and the DCR was 47.5%. Moreover, the appearance of irAE necessitated discontinuation of nivolumab in 8 cases.Conclusion① Although the efficacy of nivolumab was not significantly different from that reported by other authors, there was a tendency for a relative high proportion of patients to require treatment discontinuation because of the occurrence of irAE.② There was one case of long survival as a result of prompt management of the irAE and continuation of nivolumab treatment.

この論文にアクセスする

DOI
関連情報を調べる

CiNii Research

Patterns of recurrence after low-dose postoperative radiotherapy for head and neck squamous cell carcinoma.

Makino W, Heianna J, Ishikawa K, Kusada T, Maemoto H, Ariga T, Matayoshi A, Nakasone T, Hirakawa H, Agena S, Yamashita Y, Maeda H, Murayama S

Journal of the Egyptian National Cancer Institute ( Journal of the Egyptian National Cancer Institute ) 33 ( 1 ) 40 2021年12月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

<title>Abstract</title><sec> <title>Background</title> Postoperative chemoradiotherapy is recommended for patients with head and neck squamous cell carcinoma with positive margins or extracapsular extension at high risk of recurrence. However, high-dose radiotherapy in the head and neck region often causes severe acute and late radiation-related adversities. In our institution, the radiation dose has been relatively lower than that used in Western countries to reduce radiation-related toxicities. Therefore, in this study, we examined the treatment outcomes of low-dose postoperative chemoradiotherapy. </sec><sec> <title>Methods</title> The outcomes of 90 consecutive head and neck squamous cell carcinoma patients who received postoperative radiotherapy between June 2009 and December 2016 were retrospectively analyzed. All patients received postoperative three-dimensional conformal radiotherapy with or without concurrent systemic chemotherapy. The median patient age was 65 years. Concurrent chemoradiotherapy was administered at a total dose of 50.4 Gy in 28 fractions (daily fraction, 1.8 Gy). High-risk patients received 10.8 Gy of boost irradiation in six fractions. For radiotherapy alone, the irradiation dose was up to 54 Gy in 30 fractions and 64.8 Gy in 36 fractions for high-risk patients to increase the treatment intensity. </sec><sec> <title>Results</title> The median follow-up period was 40.5 months. The 3-year locoregional control and overall survival rates were 67.5% and 82.7%, respectively. A significantly higher proportion of patients with oral cavity carcinoma experienced locoregional failure (<italic>p</italic> = 0.004). The acute adverse events were mild, and the only late adverse event was grade 3 dysphagia (<italic>n</italic> = 3). </sec><sec> <title>Conclusion</title> This study suggests that de-escalation of the postoperative radiation dose can potentially reduce the severe adverse events of irradiation in patients while ensuring its effectiveness. In patients with oral cavity carcinoma, it might be necessary to increase the radiation dose. </sec>

この論文にアクセスする

DOI
関連情報を調べる

PubMed

癒着性中耳炎に対する一期的人工内耳手術

比嘉輝之, 我那覇章, 近藤俊輔, 親川仁貴, 安慶名信也, 平川仁, 鈴木幹男

耳鼻咽喉科臨床 ( 耳鼻咽喉科臨床学会 ) 114 ( 12 ) 909 - 916 2021年12月

掲載種別: 研究論文（その他学術会議資料等）

症例1(70歳男性)、症例2(73歳男性)。両症例とも両側難聴を主訴に当科へ受診となった。局所所見および画像所見より、いずれも癒着性中耳炎(緊張部型真珠腫Stage Ia、著明な鼓膜癒着)と診断された。治療として外耳道後壁削除型乳突削開術と外耳道閉鎖による中耳病変の摘出、および人工内耳手術を一期的に行った結果、術後は聴力は良好で、重篤な合併症や中耳病変の再発もみられなかった。

Development of Antibodies against HPV-6 and HPV-11 for the Study of Laryngeal Papilloma.

Ikegami T, Kise N, Kinjyo H, Kondo S, Suzuki M, Tsukahara N, Murakami A, Kiyuna A, Agena S, Tanaka K, Hasegawa N, Kawakami J, Ganaha A, Maeda H, Hirakawa H

Viruses ( Viruses ) 13 ( 10 ) 2021年10月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

Laryngeal papilloma (LP), which is associated with infection by human papillomavirus (HPV)-6 or -11, displays aggressive growth. The precise molecular mechanism underlying the tumorigenesis of LP has yet to be uncovered. Building on our earlier research into HPV-6, in this study, the viral gene expression of HPV-11 was investigated by quantitative PCR and DNA/RNA in situ hybridization. Additionally, newly developed antibodies against the E4 protein of HPV-6 and HPV-11 were evaluated by immunohistochemistry. The average viral load of HPV-11 in LP was 1.95 ± 0.66 × 105 copies/ng DNA, and 88% of HPV mRNA expression was found to be E4, E5a, and E5b mRNAs. According to RNA in situ hybridization, E4 and E5b mRNAs were expressed from the middle to upper part of the epithelium. E4 immunohistochemistry revealed a wide positive reaction in the upper cell layer in line with E4 mRNA expression. Other head and neck lesions with HPV-11 infection also showed a positive reaction in E4 immunohistochemistry. The distribution pattern of HPV DNA, viral mRNA, and E4 protein in LP with HPV-11 infection was quite similar to that of HPV-6. Therefore, it might be possible to apply these E4-specific antibodies in other functional studies as well as clinical applications, including targeted molecular therapies in patients with HPV-6 and HPV-11 infection.

この論文にアクセスする

DOI
関連情報を調べる

PubMed

下咽頭癌導入化学療法におけるDNA修復酵素遺伝子多型を用いた効果予測

平川仁, 池上太郎, 安慶名信也, 田中克典, 上里迅, 金城秀俊, 近藤俊輔, 真栄田裕行, 鈴木幹男

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 59回 O40 - 2 2021年10月

掲載種別: 研究論文（その他学術会議資料等）

HPV関連頭頸部癌におけるmTOR経路の検討

近藤俊輔, 安慶名信也, 平川仁, 真栄田裕行, 鈴木幹男

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 59回 O40 - 1 2021年10月

掲載種別: 研究論文（その他学術会議資料等）

　前のページ- 次のページ　

<安慶名 信也>

論文 - 安慶名 信也

<安慶名　信也>

論文 - 安慶名　信也